BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
Shares of Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) jumped in their Hong Kong trading debut on Friday, as the leading drug maker’s new IPO complemented its existing listing in Shanghai. Hengrui’s stock opened at HK$57, up 29% over its offer price, and continued to rise during the session to close up 30.87% at HK$57.65 by the midday break.
The company said it issued 224.5 million shares in the IPO, with 21.50% allocated to the Hong Kong portion for local investors. The Hong Kong tranche was 454 times oversubscribed, while the international placement was 16 times oversubscribed. The final offer price of HK$44.05 represented the top of its range, raising net proceeds of HK$9.75 billion ($1.25 billion).
Founded in 1970, Hengrui is China’s largest developer of anti-tumor and surgical drugs, and one of the country’s most innovative large pharmaceutical firms. The company reported its revenue rose 20.1% year-on-year in the first quarter of this year to 7.21 billion yuan, while its profit rose 37.2% to 1.88 billion yuan.
By Lee Shih Ta
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
BRIEF: Weibo profit doubles as AI search gains traction
BRIEF: Tuya swings to profit as premium client base expands
BRIEF: CATL jumps in trading debut as Hong Kong’s biggest IPO this year
RELATED ARTICLES
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG -
BRIEF: Hengrui Pharma to raise up to $1.3 billion in Hong Kong IPO
1276.HK 600276.SHG
-
BRIEF: Mixue surges on Hong Kong trading debut
2097.HK
-
BRIEF: Duality Biotherapies surges in Hong Kong trading debut
9606.HK
-
BRIEF: Mao Geping surges in Hong Kong trading debut
1318.HK
-
BRIEF: Auntea Jenny surges in Hong Kong trading debut
2589.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
